NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics announced a collaboration with Vanderbilt University aimed at molecular diagnostics to assess breast cancer risk in menopausal women.
The test would help physicians assess the risk of breast cancer in women who are considering hormone replacement therapy during menopause.
The terms of the deal gives Iverson global, exclusive commercialization rights for the molecular diagnostic, and Dean Sproles, CEO of Iverson, said in a statement that the firm anticipates including the new test in the Women's Health segment of Iverson's Physician's Logic portfolio later this year.
Other terms of the deal were not disclosed. Sproles added that his firm is considering additional partnerships with Vanderbilt in women's health and autoimmunity.
Iverson said that studies suggest that estrogen metabolites may be a determinant of breast cancer risk. Specific enzymes regulate the pathways associated with estrogen metabolism, and corresponding genes code for the synthesis of these enzymes. Mutations of these genes are common and have been associated with an increased risk for cancer, it said.